Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025JCO Oncology Practice

Sex-stratified risk of second malignancies in Hodgkin lymphoma survivors: A SEER-based analysis of latency and cancer type.

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTahir MalikNED University of Engineering and TechnologyVPVíctor M. Pérez‐GarcíaServicio de Salud de Castilla La ManchaJMJoseph P. MaslakInverness Research (United States)

Discussion

Loading...

Member takes

Implication

Analysis reveals second primary malignancies in Hodgkin lymphoma survivors, highlighting latency and sex-specific patterns.

Key Points

  • Elevated overall standardized incidence ratios for second malignancies were observed in Hodgkin lymphoma survivors, with notable variations by cancer type and latency.
  • Male and female survivors showed markedly elevated O/E ratios for non-hodgkin lymphoma across all latency periods, particularly within the first year post-hodgkin lymphoma.
  • Respiratory system cancers demonstrated significant elevated risks especially in the first year, highlighting the need for early surveillance in Hodgkin lymphoma survivors.
  • Findings underscore the importance of sex and latency in guiding tailored surveillance strategies for long-term cancer care in Hodgkin lymphoma survivors.

Cite This Study

Malik et al. (2025) studied this question.

synapsesocial.com/papers/68e70db290569dd607ee60f4https://doi.org/10.1200/op.2025.21.10_suppl.547
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sex-stratified risk of second malignancies in Hodgkin lymphoma survivors: A retrospective study.2026
  2. 2Burden and site-specific spectrum of second primary malignancies after adult acute myeloid leukemia: A population-based SEER standardized incidence ratio study with latency-stratified risk profiling (2000–2022).2026
  3. 3Second primary malignancy risk in Hodgkin lymphoma survivors in the modern treatment era: A SEER MP-SIR analysis, 2000–2022.2026
  4. 4Second primary malignancies in patients with chronic lymphocytic leukemia: A SEER analysis, 2000–2022.2026
  5. 5Modern Hodgkin lymphoma treatments to reduce second cancer risks: Influence of risk-adapted screening.2026